



ASX Announcement

1 December 2020

Hexima Limited lists on ASX

***Clinical-stage biotechnology company Hexima
raises \$3m in over-subscribed Public Offer***

***Hexima admitted to ASX Official List (ASX:HXL),
shares commence trading at 10:30 AM on Tuesday 1 December 2020***

***Proceeds support phase IIb clinical trial for its lead drug
candidate, HXP124, a novel topical treatment for onychomycosis***

MELBOURNE, AUSTRALIA 1 December 2020: Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing a new prescription treatment for onychomycosis (fungal nail infection), will list on the Australian Securities Exchange (ASX) today after its \$3 million public offer closed oversubscribed.

Hexima enjoyed broad support for both the public offer and a \$5.5 million private placement completed in September 2020, adding 307 new shareholders to its register. Existing Hexima shareholders were also significant participants in both capital raisings.

Hexima is investing funds raised in the public offer and private placement to complete a phase IIb clinical trial to assess its lead candidate (HXP124) as a treatment for onychomycosis. This phase IIb trial is now recruiting and enrolling patients, with 10 sites active across Australia and New Zealand. Hexima plans to also complete long-term animal toxicology studies and manufacturing scale-up for HXP124 to support late-phase clinical trials in the United States under an Investigational New Drug application.

HXP124 is a patented, easy to apply topical treatment for fungal nail infections. In a phase I/IIa clinical trial, HXP124 demonstrated significant activity and at the 12-week follow-up to 6 weeks of daily therapy, HXP124 cleared fungus from infected nails two-times more effectively than current best-in-class products while being safe and well tolerated. Hexima considers HXP124 addresses the important short comings of available treatments for onychomycosis and offers the potential for successful commercialisation.

Hexima's board and management team have extensive experience in delivering valuable pharmaceutical solutions to the market. Chief Executive Officer and Managing Director Michael Aldridge was previously CEO of ASX-listed biotechnology company, Peplin, which developed Picato, the topical treatment for actinic keratosis. Chief Operating Officer, Nicole van der Weerden, and Chief Science Officer, Marilyn Anderson, have progressed HXP124 through pre-clinical and early clinical development and remain committed to advancing HXP124 towards successful commercialisation. Hexima's Chief Development Officer, Dr Peter Welburn, brings a wealth of experience in the development of topical pharmaceutical products globally and led Picato through clinical development and onto the market.

"As a consequence of securing this funding we now have a very clear pathway to deliver the recently initiated Australian phase IIb clinical trial," said CEO Michael Aldridge. "and beyond that, critically



important milestones through to the global phase III clinical program, which is the final stage in the development of this exciting and novel product.”

Canaccord Genuity (Australia) was the lead manager for the public offer.

About Hexima

Hexima is a biotechnology company engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protecting HXP124 in major markets globally. For additional information about Hexima or participation in our clinical trial, please visit www.hexima.com.au.

This announcement is authorised for release to ASX by Michael Aldridge

Enquiries:

Dr Nicole van der Weerden
Chief Operating Officer
n.vanderweerden@hexima.com.au
Tel: +61 (0) 3 9479 1210

Join our email database to receive company announcements:

Tel: +61 (0) 3 9479 1210
Info@hexima.com.au
www.hexima.com.au